Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
FDA to weigh Tysabri fate
January 30, 2006
| A version of this story appeared in
Volume 84, Issue 5
An FDA committee will decide on March 7 whether the agency should allow the multiple sclerosis drug Tysabri back on the market. Sales of Tysabri, a monoclonal antibody codeveloped by Biogen Idec and Elan, were suspended in February 2005 after the drug was linked to progressive multifocal leukoencephalopathy, a rare nervous system disorder. Last fall, the companies submitted two-year Phase III data and more safety information on patients in the trial. They have also suggested revisions to the drug's label and have proposed a patient-monitoring program.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X